Covid-19

COVID-19

Pfizer asks for formal US approval of oral Covid-19 treatment Paxlovid

Pfizer asks for formal US approval of oral Covid-19 treatment Paxlovid
A pharmacist displays a case of Paxlovid, a Covid-19 treatment pills developed by Pfizer Inc., at a drugstore in Seoul, South Korea, 21 February 2022. EPA-EFE/YONHAP SOUTH KOREA OUT

June 30 (Reuters) - Pfizer Inc PFE.N said on Thursday it is seeking full U.S. approval for its oral COVID-19 antiviral treatment Paxlovid, which is currently available under an emergency use authorization (EUA).

Pfizer said it submitted a New Drug Application for Paxlovid to the Food and Drug Administration for the treatment of Covid-19 in vaccinated and unvaccinated people at high risk of progression to severe illness.

That is basically consistent with the drug’s current EUA, which Pfizer said covers 50% to 60% of the U.S. population, citing estimates from the U.S. Centers for Disease Control and Prevention.

A full approval could mean the company would have the option to sell Paxlovid on the open market like other drugs, depending on whether or not the U.S. government decides to stop buying the drug and providing it for free nationwide.

Also, “the company might have more control over educating the public with commercials, or however they want, to boost uptake,” said Karen Andersen, healthcare strategist at Morningstar.

The two-drug treatment taken for five days beginning shortly after onset of Covid-19 symptoms reduced the risk of hospitalization or death by 88% in non-hospitalized, high-risk adult patients in Pfizer’s clinical trial, which did not included vaccinated people.

Data from a study in Israel earlier this month showed Paxlovid reduced Covid-19 hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older, but was not found to prevent severe illness among younger adults.

More than 1.6 million courses of Paxlovid have been administered in the United States, according to data from the Department of Health and Human Services.

(Reporting by Michael Erman and Manas Mishra; Editing by Bill Berkrot and Mark Potter)

Gallery

"Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]"

Please peer review 3 community comments before your comment can be posted

We would like our readers to start paying for Daily Maverick...

…but we are not going to force you to. Over 10 million users come to us each month for the news. We have not put it behind a paywall because the truth should not be a luxury.

Instead we ask our readers who can afford to contribute, even a small amount each month, to do so.

If you appreciate it and want to see us keep going then please consider contributing whatever you can.

Support Daily Maverick→
Payment options

Become a Maverick Insider

This could have been a paywall

On another site this would have been a paywall. Maverick Insider keeps our content free for all.

Become an Insider

Every seed of hope will one day sprout.

South African citizens throughout the country are standing up for our human rights. Stay informed, connected and inspired by our weekly FREE Maverick Citizen newsletter.